Prospect: information for thepatient
Antalgin 550mg coated tablets
Naproxenosodium
Read this prospect carefully beforestarting totakethis medication, because it contains important information for you.
1. What isAntalginand for what it is used
2. What you needto know before starting to takeAntalgin
3. Howto takeAntalgin
4. Possible adverse effects
5. Storage ofAntalgin
6. Contents of the package and additional information
Antalgin contains as itsactive ingredientnaproxeno sódico, a substance that belongs to the group of medications known as nonsteroidal anti-inflammatory drugs(NSAIDs).
Antalgin is indicated for the treatment of:
It is essential to use the smallest effective dose to alleviate or control pain and not to take Antalgin for longer than necessary to manage your symptoms.
Do not take Antalgin
Warnings and precautions
Consult your doctor or pharmacist before starting to take Antalgin.
Severe skin reactions have been reported with the use of nonsteroidal anti-inflammatory drugs, appearing as red patches, generalized skin redness, ulcers, or widespread rashes accompanied by symptoms similar to the flu, including fever (see section 4). The rash may progress to generalized blisters or skin peeling. The highest risk of these severe skin reactions is during the first weeks of treatment, but they may start to develop several months after medication administration (see section 4). If you have developed any of these severe skin reactions with the use of Antalgin, do not restart treatment with Antalgin at any time. If you develop a skin rash or these symptoms, stop taking Antalgin and contact your doctor or seek immediate medical attention.
Be cautious in the following situations:
Medications like Antalgin may be associated with a moderate increase in the risk of suffering heart attacks ("myocardial infarctions") or strokes. This risk is more likely to occur when using high doses and prolonged treatment. Do not exceed the recommended dose or treatment duration.
If you have heart problems, a history of strokes, or think you may be at risk for these conditions (for example, you have high blood pressure, diabetes, high cholesterol, or are a smoker), you should consult this treatment with your doctor or pharmacist.
Additionally, this type of medication may cause fluid retention, especially in patients with heart failure and/or high blood pressure (hypertension).
Other medications and Antalgin
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
This is very important because Antalgin may alter the way other medications work. It is essential to inform your doctor if you take any of the following medications:
You may need your doctor to adjust the dose of one of the two medications. Consult your doctor if you have any doubts about these points..
Antalgin with food and beverages
It is recommended to take the tablets during meals or immediately after eating to reduce the possibility of stomach discomfort.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Antalgin should not be administered during pregnancy, childbirth, or breastfeeding.
Do not take Antalgin if you are in the last 3 months of pregnancy, as it may harm the fetus or cause problems during delivery. It may cause kidney and heart problems in your fetus. It may affect your tendency and that of your baby to bleed and delay or prolong delivery more than expected.
Due to the association of administering medications like Antalgin with an increased risk of congenital anomalies/abortions, do not take Antalgin during the first and second trimesters of pregnancy unless it is strictly necessary and your doctor advises it. If you need treatment during this period or while trying to become pregnant, you should take the minimum dose for the shortest time possible. From week 20 of pregnancy, Antalgin may cause kidney problems in your fetus if taken for more than a few days, which may lead to low amniotic fluid levels surrounding the baby (oligohydramnios). If you need treatment for a period longer than a few days, your doctor may recommend additional monitoring.
For fertile women, it is essential to consider that medications like Antalgin have been associated with a decrease in the ability to conceive.
Driving and operating machinery
Antalgin should be used with caution in patients whose activity requires attention and who have observed dizziness or visual disturbances during treatment with this medication.
Antalgin contains sodium
This medication contains 50 mg of sodium (the main component of table salt/for cooking) in each tablet. This is equivalent to 2.5% of the recommended daily maximum sodium intake for an adult.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist.In case of doubt, consult your doctor or pharmacist again..
Your doctor will indicate the duration of your treatment with Antalgin.
The recommended dose is:
Adults
The usual daily dose is 1 or 2 tablets (550 mg or 1100 mg of naproxeno sódico). As an initial dose, it is recommended to administer 1 tablet (550 mg of naproxeno sódico) followed by half a tablet (275 mg of naproxeno sódico) every 6 or 8 hours, depending on the intensity of the process.These doses may be modified by your doctor's indication.
For the treatment ofrheumatoid arthritis,osteoarthritisandankylosing spondylitis: the initial dose is usually 1 tablet (550 mg of naproxeno sódico) taken twice a day (in the morning and at night) or 2 tablets (1100 mg of naproxeno sódico) taken once a day.
For the treatment of acute episodes of gout:the initial dose is usually 1 and a half tablets (825 mg of naproxeno sódico) followed by half a tablet (275 mg of naproxeno sódico) every 8 hours until you no longer feel pain. Consult your doctor about the duration of treatment.
Por the treatment of dysmenorrhea (menstrual pain): the initial dose is usually 1 tablet (550 mg of naproxeno sódico) followed by half a tablet (275 mg of naproxeno sódico) every 6 or 8 hours.
Por the treatment of migraine crises:the initial dose is 1 and a half tablets (825 mg of naproxeno sódico) when the first symptoms appear, followed by half a tablet (275 mg of naproxeno sódico) when 30 minutes have passed since the initial dose.
Por the treatment of menorrhagia (pain associated with excessive menstrual bleeding): the initial dose on the first day of menstruation is between 1 and a half and 2 and a half tablets (825 mg and 1375 mg of naproxeno sódico)taken in two doses a day. Continue with a dose of 1 or 2 tablets a day (550 mg or 1100 mg of naproxeno sódico) taken in two doses a day, for a maximum of 4 days.
Use in patients over 65 years or with kidney and/or liver disease
In patients over 65 years or with kidney or liver disease, it is recommended to reduce the dose and use the lowest effective dose for the shortest possible time. Consult your doctor.
Use in children and adolescents
This medication is not recommended for use in children under 16 years old.
Administration form:
This medication is taken orally.
The tablet can be divided into equal doses.
Swallow the tablets with a sufficient amount of liquid, a glass of water or another liquid, preferably during or after meals.
Always take the lowest effective dose.
If you take more Antalgin than you should
If you have taken more Antalgin than you should, consult your doctor or pharmacist immediately.
The symptoms of overdose are characterized by drowsiness, stomach burning, indigestion, nausea, vomiting, and in some cases, convulsions.
In case of accidental or voluntary overdose, proceed with gastric lavage and initiate symptomatic treatment. The rapid administration of 50-100 g of activated charcoal in the form of a water suspension reduces the absorption of the medication.
In case of overdose or accidental ingestion, consult the Toxicological Information Service, Telephone (91) 562.04.20.
If you forgot to takeAntalgin
Do not take a double dose to compensate for the missed doses, take the dose when you remember and continue with the next dose.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
The side effects that may occur during treatment with this medicine, and that have been observed with a very rare frequency (in less than 1 in 10,000 patients) are:
Gastrointestinal disorders:The most frequent side effects observed with Antalgin are of a gastrointestinal nature (affecting the stomach and intestines).
It may cause inflammation, bleeding (in some cases fatal, especially in the elderly), peptic ulcers, perforation, and obstruction of the upper or lower gastrointestinal tract (digestive system). Cases of esophagitis (inflammation of the esophagus), gastritis (inflammation of the stomach lining), pancreatitis (inflammation of the pancreas), stomatitis (inflammation of the oral mucosa), and worsening of ulcerative colitis and Crohn's disease have been observed.Also, cases of stomach acid, dyspepsia (digestive disorders), abdominal pain, nausea, vomiting, diarrhea, constipation, flatulence (gas), hematemesis (vomiting blood), and melena (black stools) have been observed.
Blood and lymphatic system disorders:agranulocytosis (increase/decrease of certain white blood cells), aplastic and hemolytic anemia (reduction of red blood cells, white blood cells, and platelets in the blood), eosinophilia (increase of certain white blood cells in the blood), leucopenia (decrease of white blood cells in the blood), thrombocytopenia (decrease of platelets), lymph node enlargement, and affection of other organs of the body (drug reaction with eosinophilia and systemic symptoms known as DRESS). See section 2.
Immune system disorders:anaphylactoid reactions (acute allergic reaction), angioneuritic edema (inflammation of the skin, mucosa, and viscera), elevated body temperature.
Metabolism and nutrition disorders:hypercalcemia (increase of calcium concentration in the blood).
Psychiatric disorders:difficulty concentrating, depression, sleep disturbances.
Nervous system disorders:dizziness, somnolence, headaches, sensation of dizziness, vertigo, cognitive dysfunction, aseptic meningitis (inflammation of the meninges), convulsions, insomnia.
Eye disorders:vision disturbances, corneal opacity, papillitis (inflammation of the papilla), retrobulbar optic neuritis (inflammation of the optic nerve), and papillary edema.
Ear and labyrinth disorders:auditory disturbances, tinnitus (ringing in the ears), hearing loss.
Cardiac disorders:palpitations, congestive heart failure (heart's inability to pump blood), hypertension (high blood pressure). Medicines like Antalgin may be associated with a moderate increase in the risk of suffering a heart attack ("myocardial infarction") or stroke.
Vascular disorders:vasculitis (inflammation of blood vessels), edema.
Respiratory, thoracic, and mediastinal disorders:asthma, eosinophilic pneumonitis, dyspnea (shortness of breath), pulmonary edema.
Infections and infestations:aseptic meningitis.
Hepatobiliary disorders:hepatitis (inflammation of the liver), jaundice (yellow discoloration of the skin), and elevated liver enzymes. Medicines like Antalgin may be associated with rare cases of liver damage.
Skin and subcutaneous tissue disorders:cutaneous hemorrhage, pruritus, capillary hemorrhage, generalized skin eruptions, sweating, alopecia, skin peeling, lichen planus (cutaneous disease of small flat nodules), vesicular rash, skin redness, systemic lupus erythematosus (autoimmune disease with typical skin symptoms, rash, and skin redness), severe bullous reactions such as Stevens-Johnson syndrome (skin rash resembling a map) and toxic epidermal necrolysis, allergy, photosensitivity reactions including rare cases where the skin takes on a porphyria cutanea tarda appearance, pseudoporphyria (defect of liver enzymes) or epidermolysis bullosa. If cutaneous fragility, blister formation, or other symptoms indicative of pseudoporphyria occur, treatment should be suspended and the patient monitored.
Musculoskeletal, connective tissue, and bone disorders:muscle pain, asthenia.
Renal and urinary disorders:hematuria, interstitial nephritis (renal inflammation with yellow-brown discoloration), nephrotic syndrome, renal disease, renal insufficiency, papillary necrosis (death of cells forming the renal papillae due to metabolic alteration).
Reproductive and breast disorders:infertility.
General disorders and administration site conditions:general malaise, pyrexia (chills and fever), thirst, sore throat, a characteristic cutaneous allergic reaction known as fixed drug eruption, which usually reappears at the same site upon re-exposure to the drug and may appear as red, rounded, or oval patches and skin swelling, urticaria (hives), and pruritus.
Complementary examinations:abnormal values of liver function tests, elevated serum creatinine, hyperkalemia.
If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this prospectus.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use: www.notificaRAM.es/. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keepthis medicationout of the sight and reachof children.
Do not use Antalgin after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through drains or in the trash.Deposit the containers and unusedmedicines at the SIGREPoint of the pharmacy.In case of doubt, ask your pharmacist how to dispose of the containers and unused medicines. By doing so, you will help protect the environment.
Composition of Antalgin
-The active ingredient is naproxen sodium. Each tablet contains 550 mg of naproxen sodium (equivalent to 500 mg of naproxen)
-The other components (excipients) are: microcrystalline cellulose, povidone, talc, magnesium stearate, hypromellose (E464), macrogol, titanium dioxide (E-171), indigotin lake (E-132) and purified water.
Appearance of the product and content of the container
Antalgin are film-coated tablets, oval in shape, blue in color, and with the inscription NPS 550 on one of the faces of the tablet. The tablet is breakable (can be divided into two equal doses).
It is presented in containers of 10 and 40 film-coated tablets.
Holder of the marketing authorization:
Atnahs Pharma Netherlands B.V.
Copenhagen Towers
Ørestads Boulevard 108, 5.tv
DK-2300 København S
Denmark
Responsible for manufacturing:
RECIPHARM LEGANÉS S.L.U.
C/ Severo Ochoa, 13.Pol. Ind. Leganés
28914 Madrid
RECIPHARM FONTAINE SAS
Rue des Près Potets
21121 Fontaine-Lès-Dijon – France
Atnahs Pharma Denmark ApS
Copenhagen Towers
Ørestads Boulevard 108, 5.tv
DK-2300 København S
Denmark
Misom Labs Ltd
Malta Life Sciences Park
LS2.01.06
Industrial Estate
San Gwann, SGN 3000, Malta
Local representative
Laboratorios Rubió, S.A.
Industria, 29 - Pol. Ind. Comte de Sert
08755 Castellbisbal (Barcelona)
Spain
Last review date of this leaflet:February 2025
“Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/”
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.